CADL Stock Analysis
CA
Uncovered
Candel Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. The Company has two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus, and herpes simplex virus (HSV) constructs, respectively. Its two product candidates include CAN-2409 and CAN-3110. CAN-2409 is an adenovirus-based, replication-deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. Its enLIGHTEN Discovery Platform is the systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.